Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 811 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: sterile saline solution Clear all
Terminated Not applicable Interventional

Platelet Lysate vs Saline for Lumbosacral Radiculopathy

NCT06924853
View directory record Official record
Conditions
Lumbosacral Radiculopathy, Lumbar Radiculopathy
Interventions
Platelet lysate, Saline control
Other
Lead sponsor
Regenexx, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Broomfield, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 20, 2026, 11:02 PM EDT
Enrolling by invitation Phase 4 Interventional

Efficacy and Safety of Intraosseous Antibiotic Prophylaxis in Total Hip Replacement

NCT07549542
View directory record Official record
Conditions
Antibiotic Prophylaxis Surgery
Interventions
CeFAZolin 1000 MG, Saline (0.9%, sterile, for infusion)
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Somerset, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Phase 2 Interventional Results available

Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease

NCT01713400
View directory record Official record
Conditions
Graft vs. Host Disease
Interventions
Ustekinumab, Placebo, Tacrolimus (TAC), Sirolimus
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 20, 2026, 11:02 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions

NCT04540900
View directory record Official record
Conditions
Skin Roughness, Wrinkle, Fine Lines, Skin Thickness
Interventions
KB301, Placebo
Biological · Other
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2029
U.S. locations
4
States / cities
Campbell, California • Newport Beach, California • Rancho Santa Margarita, California + 1 more
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 20, 2026, 11:02 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Neuro Biomarkers of Smoking Behavior

NCT03811951
View directory record Official record
Conditions
Smoking Cessation
Interventions
Novolin R
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
21 Years to 40 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 20, 2026, 11:02 PM EDT
Terminated Phase 1 Interventional

Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors

NCT00238173
View directory record Official record
Conditions
Bone Marrow Suppression, Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Long-term Effects Secondary to Cancer Therapy in Children
Interventions
filgrastim, acetylcysteine, carboplatin, cyclophosphamide, etoposide phosphate, mannitol, sodium thiosulfate
Biological · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
1 Year to 18 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 20, 2026, 11:02 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

NCT03970447
View directory record Official record
Conditions
Glioblastoma
Interventions
Temozolomide, Lomustine, Regorafenib, Radiation, Paxalisib, VAL-083, VT1021, Troriluzole, ADI-PEG 20, AZD1390, Tinostamustine
Drug · Radiation · Biological
Lead sponsor
Global Coalition for Adaptive Research
Other
Eligibility
18 Years and older
Enrollment
2,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
42
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 20, 2026, 11:02 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT31-1 for Treating ARDS

NCT07449572
View directory record Official record
Conditions
ARDS (Acute Respiratory Distress Syndrome)
Interventions
HT31-1, Saline (0.9%, sterile, for infusion)
Drug · Other
Lead sponsor
HTIC, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome

NCT02165111
View directory record Official record
Conditions
Scleroderma, Raynaud's Syndrome
Interventions
Onabotulinumtoxin A, sterile saline solution
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Not applicable Interventional Results available

Safety and Effectiveness of Monovisc® Injection for Osteoarthritis of the Knee

NCT00653432
View directory record Official record
Conditions
Osteoarthritis
Interventions
Monovisc®, Saline
Device · Other
Lead sponsor
Anika Therapeutics, Inc.
Industry
Eligibility
35 Years to 75 Years
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
30
States / cities
Hoover, Alabama • Mesa, Arizona • Phoenix, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Phase 3 Interventional

Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis

NCT04102371
View directory record Official record
Conditions
Shock, Septic
Interventions
Lactated Ringer, Normal Saline, Plasma-lyte
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Months to 17 Years
Enrollment
9,041 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
22
States / cities
Davis, California • Los Angeles, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 20, 2026, 11:02 PM EDT
Recruiting Not applicable Interventional

Macrophage Programing in Acute Lung Injury: MiniBAL

NCT05767671
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Ventilator Associated Pneumonia
Interventions
Non-Bronchoscopic Mini Bronchoalveolar Lavage
Other
Lead sponsor
William Janssen, MD
Other
Eligibility
18 Years to 99 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Phase 2Phase 3 Interventional

A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix

NCT00264732
View directory record Official record
Conditions
Uterine Cervical Dysplasia
Interventions
Amolimogene, Placebo
Drug · Other
Lead sponsor
Eisai Inc.
Industry
Eligibility
13 Years to 25 Years · Female only
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects

NCT05285137
View directory record Official record
Conditions
Healthy
Interventions
CD388 Injection, Saline placebo
Combination Product · Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 20, 2026, 11:02 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS

NCT05938036
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS)
Interventions
ALT-100 mAb, ALT-100 (Placebo)
Drug
Lead sponsor
Aqualung Therapeutics Corp.
Industry
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis

NCT04304144
View directory record Official record
Conditions
AL Amyloidosis
Interventions
CAEL-101, SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD), Daratumumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Stanford, California • Detroit, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Lumify™ Eyedrops on Eyelid Position

NCT03782701
View directory record Official record
Conditions
Eyelid Droop
Interventions
Brimonidine tartrate ophthalmic solution 0.025%, Sterile balanced saline solution
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects

NCT04920786
View directory record Official record
Conditions
Alzheimer Disease
Interventions
TB006, Sterile saline (Placebo)
Drug · Other
Lead sponsor
TrueBinding, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria

NCT03392896
View directory record Official record
Conditions
Primary Hyperoxaluria
Interventions
DCR-PHXC, Placebo
Drug
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
6 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Phase 1Phase 2 Interventional

Zofin (Organicell Flow) for Patients With COVID-19

NCT04384445
View directory record Official record
Conditions
Corona Virus Infection, COVID-19, SARS, Acute Respiratory Distress Syndrome
Interventions
Zofin, Placebo
Biological · Other
Lead sponsor
ZEO ScientifiX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 20, 2026, 11:02 PM EDT
Withdrawn Phase 2 Interventional

Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)

NCT01565395
View directory record Official record
Conditions
Parkinson Disease, Amyotrophic Lateral Sclerosis
Interventions
Incobotulinum Toxin A, placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
20 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 20, 2026, 11:02 PM EDT
Terminated Not applicable Interventional

Amnio-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone

NCT06572839
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Amnio-Maxx
Other
Lead sponsor
Capsicure, LLC
Network
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
12
States / cities
Athens, Alabama • San Diego, California • Coral Gables, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Not applicable Interventional Results available

Microfragmented Adipose Tissue Versus Platelet-rich Plasma for Knee Osteoarthritis: a Randomized Comparative Trial

NCT04351087
View directory record Official record
Conditions
Osteoarthritis, Knee, Microfragmented Adipose Tissue, Platelet-Rich Plasma
Interventions
Platelet Rich Plasma
Device
Lead sponsor
Ohio State University
Other
Eligibility
25 Years to 75 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 20, 2026, 11:02 PM EDT
No Longer Available No phase listed Expanded access Accepts healthy volunteers

Direct Antibiotic Delivery of Cefazolin Into Soft Tissue Infections Using Subcutaneous Injection and Ultrasonic Dispersion

NCT01238276
View directory record Official record
Conditions
Infection, Soft Tissue, Infection, Wound, Cellulitis, Diabetic Foot Ulcer
Interventions
Cefazolin, Silberg Tissue Preparation System
Drug · Device
Lead sponsor
Sonescence, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Sebastopol, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 20, 2026, 11:02 PM EDT